Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CLNN Clene Inc
- Stocks
- Healthcare
- NASDAQ: CLNN
Price (delayed)
$2.57
Market cap
$23.09M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.04
Enterprise value
$34.14M
Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new
Highlights
CLNN's EPS has surged by 56% year-on-year and by 29% since the previous quarter
The equity has grown by 44% from the previous quarter
The revenue fell by 44% YoY but it rose by 2.3% QoQ
The gross profit has contracted by 43% YoY
CLNN's quick ratio is down by 23% from the previous quarter and by 14% YoY
Key stats
What are the main financial stats of CLNN
Market
Valuations
Earnings
Shares outstanding
8.98M
Market cap
$23.09M
Enterprise value
$34.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
64.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
97.53
Revenue
$350,000
Gross profit
$276,000
Operating income
-$27.94M
Net income
-$29.07M
EBIT
-$25.64M
EBITDA
-$23.48M
Free cash flow
-$19.26M
Per share
Balance sheet
Liquidity
EPS
-$4.04
EPS diluted
-$4.04
Free cash flow per share
-$2.18
Book value per share
-$0.58
Revenue per share
$0.04
TBVPS
$2.87
Total assets
$25.31M
Total liabilities
$30.29M
Debt
$20.94M
Equity
-$4.97M
Working capital
$3.91M
Debt to equity
-4.21
Current ratio
1.36
Quick ratio
0.92
Net debt/EBITDA
-0.47
Margins
Efficiency
Dividend
EBITDA margin
-6,708.3%
Gross margin
78.9%
Net margin
-8,306%
Operating margin
-7,982%
Return on assets
-93.4%
Return on equity
N/A
Return on invested capital
-113.5%
Return on capital employed
-176.2%
Return on sales
-7,326.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLNN stock price
How has the Clene stock price performed over time
Intraday
-0.39%
1 week
-2.28%
1 month
-14.9%
1 year
-66.67%
YTD
-51.6%
QTD
-16.56%
Financial performance
How have Clene's revenue and profit performed over time
Revenue
$350,000
Gross profit
$276,000
Operating income
-$27.94M
Net income
-$29.07M
Gross margin
78.9%
Net margin
-8,306%
The revenue fell by 44% YoY but it rose by 2.3% QoQ
The gross profit has contracted by 43% YoY
The net income is up by 40% YoY and by 26% QoQ
The company's net margin rose by 28% QoQ but it fell by 5% YoY
Price vs fundamentals
How does CLNN's price correlate with its fundamentals
Growth
What is Clene's growth rate over time
Valuation
What is Clene stock price valuation
P/E
N/A
P/B
N/A
P/S
64.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
97.53
CLNN's EPS has surged by 56% year-on-year and by 29% since the previous quarter
The equity has grown by 44% from the previous quarter
The stock's price to sales (P/S) is 88% less than its 5-year quarterly average of 553.8 and 28% less than its last 4 quarters average of 90.2
The revenue fell by 44% YoY but it rose by 2.3% QoQ
Efficiency
How efficient is Clene business performance
CLNN's return on sales is up by 29% since the previous quarter but it is down by 3.1% year-on-year
Clene's return on invested capital has increased by 24% QoQ and by 10% YoY
The ROA has grown by 14% from the previous quarter but it has contracted by 8% YoY
Dividends
What is CLNN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLNN.
Financial health
How did Clene financials performed over time
The total assets is 16% smaller than the total liabilities
The total assets has declined by 44% year-on-year and by 7% since the previous quarter
Clene's total liabilities has decreased by 26% YoY and by 16% from the previous quarter
Clene's debt to equity has shrunk by 155% YoY and by 79% QoQ
The equity has grown by 44% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.